PTP1B inhibitor Ertiprotafib is also a potent inhibitor of IκB kinase β (IKK-β)

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 10, 2007, Pages 2728-2730

  Shrestha, Suja ^a   Bhattarai, Bharat Raj ^a   Cho, Heeyeong ^b   Choi, Joong Kwon ^b   Cho, Hyeongjin ^a  

^a Inha University   (South Korea)

^b Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

Diabetes; Ertiprotafib; I B kinase; IKK ; Inflammation; PTP1B

Indexed keywords

ERTIPROTAFIB; I KAPPA B KINASE BETA; PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; IC 50;

ANIMALS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; I-KAPPA B KINASE; PHENYLPROPIONATES; PROTEIN-TYROSINE-PHOSPHATASE; THIOPHENES;

ANIMALIA;

EID: 34247389285     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.03.001     Document Type: Article

References (19)

1. Smyth S., and Heron A. Nat. Med. 12 (2006) 75
2. Sone H., Suzuki H., Takahashi A., and Yamada N. Trends Mol. Med. 7 (2001) 320
3. Yki-Järvinen H. N. Engl. J. Med. 351 (2004) 1106
4. Bastaki S. Int. J. Diab. Metab. 13 (2005) 111
5. Moller D.E. Nature 414 (2001) 821
6. Elchebly M., Payette P., Michaliszyn E., Cromlish W., Collins S., Loy A.L., Normandin D., Cheng A., Himms-Hagen J., Chan C.-C., Ramachandran C., Gresser M.J., Tremblay M.L., and Kennedy B.P. Science 283 (1999) 1544
7. Klaman L.D., Boss O., Peroni O.D., Kim J.K., Martino J.L., Zabolotny J.M., Moghal N., Lubkin M., Kim Y.-B., Sharpe A.H., Stricker-Krongrad A., Shulman G.I., Neel B.G., and Kahn B.B. Mol. Cell Biol. 20 (2000) 5479
8. Zinker B.A., Rondinone C.M., Trevillyan J.M., Gum R.J., Clampit J.E., Waring J.F., Xie N., Wilcox D., Jacobson P., Frost L., Kroeger P.E., Reilly R.M., Koterski S., Opgenorth T.J., Ulrich R.G., Crosby S., Butler M., Murray S.F., McKay R.A., Bhanot S., Monia B.P., and Jirousek M.R. Proc. Natl. Acad. Sci. U.S. A. 99 (2002) 11357
9. Pei Z., Liu G., Lubben T.H., and Szczepankiewicz B.G. Curr. Pharm. Des. 10 (2004) 3481
10. Zhang Z.-Y., and Lee S.-Y. Expert Opin. Investig. Drugs 12 (2003) 223
11. Erbe D.V., Wang S., Zhang Y.L., Harding K., Kung L., Tam M., Stolz L., Xing Y., Furey S., Qadri A., Klaman L.D., and Tobin J.F. Mol. Pharmacol. 67 (2005) 69
12. Yuan M., Konstantopoulos N., Lee J., Hansen L., Li Z.-W., Karin M., and Shoelson S.E. Science 293 (2001) 1673
13. 2 1420 Multilabel Counter, Perkin-Elmer, Wellesley, MA, USA). The counter was set at an excitation wavelength of 340 nm, with a 400 μs delay and emission collection for 400 μs at 615 nm.
14. Yin M.-J., Yamamoto Y., and Gaynor R.B. Nature 396 (1998) 77
15. Alpert D., and Vilček J. J. Biol. Chem. 275 (2000) 10925
16. Karin M., Yamamoto Y., and Wang Q.M. Nat. Rev. Drug Discov. 3 (2004) 17
17. Chen L.-W., Egan L., Li Z.-W., Greten F.-R., Kagnoff M.F., and Karin M. Nat. Med. 9 (2003) 575
18. Arkan M.C., Hevener A.L., Greten F.R., Maeda S., Li Z.-W., Long J.M., Wynshaw-Boris A., Poli G., Olefsky J., and Karin M. Nat. Med. 11 (2005) 191
19. Cai D., Yuan M., Frantz D.F., Melendez P.A., Hansen L., Lee J., and Shoelson S.E. Nat. Med. 11 (2005) 183